3 employees
OrisDX provides a saliva-based molecular detection method to check oral cavity pre-malignancies and cancers.
2021
$665K
from 1 investors over 1 rounds
OrisDX raised $665K on June 7, 2022
Investors: Polsky Center at the University of Chicago